VITTAILTV Ltd.

Developing Novel Solutions To Treat Human Papilloma Virus -Related 

Cancers and Prostate Cancer

Targeting Major UnmetMedical Needs

A first in class, small molecule inhibitor of a key protein (E6AP)Developed to preclinical stage prior to licensing Protected by intellectual property, including composition of matter patent(s)

Therapeutic development based on a key discovery by the founders:The Company is targeting treatments for prostate cancer and HPV-related cancers that will be:

a. b.c.

Risk minimised through:Experienced management team (drug discovery methodology, global innovators of the underlying knowhow)Experienced Board with extensive biotech start-up and development track recordIdentification of key biomarkers and the clinical nexus between E6AP and multiple cancerEstablished contracts with key service providers (SYNthesis Research, Peter Mac).Established collaborations for disease models and clinical consultationCurrently no competing IP

18%

Prostate

88%

Anus

41%

Vagina

and Vulva

44%

Oral

and Larynx

31%

Oral and

Pharynx

Penis

51%

88%

Cervix

Life expectancy HPVRelatedCancers

Cervical Cancer

Oral cavity andLarynx

Anal Cancer

Oral Cavity andPharynx Cancer

528,000

358,000

40,000

95 %

44%

88%

67.1%  - all cases17.3% - metastatic disease

60.7% - all cases34.3% - metastatic disease

67% - all cases30% -metastatic

disease

GlobalNew Cases

(pa)

Percentage ofCancers

Treatable by Vittail

Vaginal and VulvarCancers

Penile Cancer #

Other Cancers

Prostate Cancer

49,000

26,000

Global NewCases (pa)

41%

51%

18%

96,000

200,000

31%

PercentageTreatable by

Vittail

5 year survival

64.5% - all cases38.5% - metastatic disease

95% - all cases73% - metastatic disease

Life expectancy 5 year survival

98.6% for all

29.8% metastatic disease

72.1% - all cases17.4% - metastatic disease

Market Size

Target Markets

Tom Peat, Ph.D. John Deadman, Ph.D.BSc in medicinal chemistry, PhD in the field ofdrug discovery.Over 25 years experience in Drug Discovery andDevelopment.Managed multidisciplinary teams globally forresearch projects and regulatory purposesunder  GMP.Developed drugs under IND to Phase III clinicaltrials.Experience at management and board level inbiotech in Europe, Australasia and China.International biotech consultant with multiplepublications, grants and inventions (multiplepatents including granted patents).

Founders: Experienced Innovators

VITTAIL has an experienced clinical advisory panel including:•Prof. S. Sandhu for castration resistant prostate cancer•Prof. B. Solomon for HPV driven cancers

BS in Biochemistry and Biophysics - UC  Berkeley; PhDin Molecular, Cellular &  Biophysical Studies - ColumbiaUniversity.  First scientist hired by SGX Pharmaceuticals, appointedDirector of Structural Biology. VP of Proteomics at OpenEye Scientific  Software,established San Diego facility.  Established in CSIRO fragment screening program:used by multiple international biotech andpharmaceutical companies.  Helped develop inhibitors: PRMT5 sold to Merck USAin 2016 for US$500M, other inhibitors sold to Pfizer in2018 for US$490M.Experienced in solving >1000 protein structures,multiple publications & co-founder of  MecRX & Vittail.

PhD - Walter and Eliza Hall, discovered Bmi1; postdoctoral research at the WeizmannInstitute;  Major discovery of the  degradationof p53 by Mdm2.World-leading researcher in tumoursuppression with a focus on cancer biology ofthe ubiquitin proteasome system.Led 2 large consortia (Europe and Australiawith over $27m in research funding),supervised over 80  students/research staff.Multiple awards/fellowships (includingNHMRC and the Victorian Endowment forScience Knowledge and Innovation).

Ygal Haupt, Ph.D.

SAB

Fragment-Based Drug Design (FBDD) screening processPartner Organisations’ Roles

Biological assaysAlphaScreen activity/counter- 

screen/selectivity)ubiquitination, pre-clinical

mouse models

Medicinal chemistryFragment optimisation

physicochemical optimisation(ADMET/ “drug likeness”)X-ray crystallography 

Fragments and ligands usingAustralian Synchrotron

Fragment Libraries

Biophysical assaysSPR and STD NMR

Preclinical lead drug

CSIRO

CSIROBio21

SynchrotronCSIRO

PeterMac

SYNthesisCDCO

VITTAIL

The Target: E6-AssociatedProtein (E6AP)

E6AP is critical for high-risk HPV-related and prostate cancers

E6AP ordinarily regulates the expression of  three key tumour

suppressors in the body - p53, PML and p27.

In cancers E6AP is ‘over activated’ causing the destruction of

tumour suppressors.

VITTAIL’s therapeutic approach is to inhibit E6AP to restore the

body’s tumour suppressive capacity.

E6AP promotes cancer by degrading the patient’s tumoursuppressing protein (PML) in prostate cancer

Prostate

20

40

60

80

100

0

Lymphom

a

Germ C

ellLung

Breast

Colon

CNS

Complete

Loss

Partial

Loss

Major cancers in which thekey target of E6AP is lost.These are relevant cancersfor VITTAILS’s noveltherapeutic approach

Targeting E6AP inhibits prostate cancerprolonging the life of experimental mice.

The growth of human prostate cancer is significantly inhibited by depletingE6AP in experimental models. Depletion of E6AP restores the body’s anti-canceractivities.

With

E6AP

Without

E6AP

Timeline for Drug Development

Capital-efficient structure & key discovery partnership with CSIRO provides a rapid path

to a commercialisation event

Assay Platform

Establishment

Fragment

Screen

Multiple

Hits/Early Leads

IdentifiedLicensing

event

Compound

Optimization

Test Compound

as E6AP

inhibitor in

cancer models

Negotiate

Licensing

transaction/

M&A

2 0 2 42 0 2 0 - 2 1 2 0 2 1 - 2 0 2 2 2 0 2 3

Proof

of concept

data

Offer Summary

Amount to be Raised

Offer Price PerPrefence Share

Number of New PreferenceShares Being Offered

Valuation of ViITTAIL pre-raising

$1.5 Million

(with the ability to accept over subscriptions)

Total Number of Shares After Raising

(including Ordinary Shares and

Preference Shares)

Indicative Capitalisation ofCompany After Raising

$1

1.5 Million

(with the ability to accept over subscriptions)

$1.5 Million

2 Million Preference Shares

1 Million Ordinary Shares

Additional shares will also be issued if there are any

oversubscriptions

$3 Million